Manipulation of the aryl hydrocarbon receptor in the skin via a photoactivated L-tryptophan preparation

Considerations in the clinical presentation, pathophysiology, and management of atopic dermatitis in patients with skin of colour

Is PBS subsidisation cap for Atopic Eczema reducing newer and improved therapies over the 5 years?

Upadacitinib for the treatment of moderate-to-severe atopic dermatitis in real-world clinical practice

Dupilumab-associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with malassezia-specific immunoglobulin e levels mirroring cli

Lebrikizumab use in Atopic Dermatitis: An update on current evidence

Keratosis Pilaris Area Index (KPAI) and KP-IGA: The validation of an objective investigator global assessment (IGA) tool for assessing keratosis pilaris

Improvement in symptoms of atopic dermatitis (AD) and AD-related quality of life with dupilumab treatment in adults: 24-week results of the DUPISTAD study

Treatment outcomes for up to 2 years in patients aged <12 years with inadequately controlled moderate-to-severe atopic dermatitis: Real-world data from PEDISTAD